Synthesis of PNA-Alkylator conjugates to target the HER-2/neu promoter
Zhanna V. Zhilina(University of Arizona), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Meghan C. Boros(University of Arizona), Lenka Stankova(Arizona Oncology), Amy Ziemba, Peter E. Nielsen(University of Copenhagen)
Cancer Research
May 1, 2005
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k